A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

The recruitment status of this study is unknown because the information has not been verified recently.

Verified July 2004 by Trimeris.
Recruitment status was Active, not recruiting

Sponsor:

Information provided by:

Trimeris

ClinicalTrials.gov Identifier:

NCT00048217

First received: October 28, 2002

Last updated: June 23, 2005

Last verified: July 2004

History of Changes

Tracking Information
First Received Date ^ICMJE	October 28, 2002
Last Updated Date	June 23, 2005
Start Date ^ICMJE	Not Provided
Primary Completion Date	Not Provided
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00048217 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
Official Title ^ICMJE	Not Provided
Brief Summary	Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 1 Phase 2
Study Design ^ICMJE	Allocation: Randomized Masking: Open Label Primary Purpose: Treatment
Condition ^ICMJE	HIV Infections
Intervention ^ICMJE	Drug: T-1249
Study Arm (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Active, not recruiting
Enrollment ^ICMJE	Not Provided
Completion Date	Not Provided
Primary Completion Date	Not Provided
Eligibility Criteria ^ICMJE	Inclusion Criteria: Completion T1249-102; Currently failing a T-20 containing regimen Exclusion Criteria: Non-completion of T1249-102.
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT Number ^ICMJE	NCT00048217
Other Study ID Numbers ^ICMJE	T1249-105
Has Data Monitoring Committee	Not Provided
Responsible Party	Not Provided
Study Sponsor ^ICMJE	Trimeris
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Trimeris
Verification Date	July 2004
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top